Insulin Human
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Insulin Human: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin human is a peptide hormone used to treat diabetes mellitus (Type 1 and Type 2), replacing or supplementing endogenous insulin to regulate blood glucose levels. The TxGNN model predicts it may be effective for Autoimmune Oophoritis, with 0 clinical trials and 0 publications currently supporting this direction. The overall evidence level is L5 (AI prediction only), and this candidate is not recommended for further development at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes Mellitus (Type 1 & Type 2) |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Insulin human is a peptide hormone that binds the insulin receptor to facilitate cellular glucose uptake and regulate carbohydrate, fat, and protein metabolism. Its clinical role in diabetes mellitus — replacing absent or insufficient endogenous insulin — is well-established across decades of practice.
Autoimmune oophoritis is strongly associated with polyglandular autoimmune syndrome (APS Type 1/2), which frequently co-occurs with Type 1 Diabetes Mellitus (T1DM). Both conditions share the same underlying immune dysregulation: T-cell mediated destruction of endocrine tissue and circulating autoantibodies targeting organ-specific antigens. TxGNN likely captured these shared immunological nodes in the biomedical knowledge graph — particularly the overlap in autoimmune endocrine targets — to generate this high-confidence score.
However, insulin itself has no known direct therapeutic effect on ovarian autoimmunity. Patients with both T1DM and autoimmune oophoritis require insulin for glucose management, but this represents comorbidity treatment, not repurposing. The high TxGNN score reflects shared biological context rather than a tractable therapeutic hypothesis. No preclinical or clinical evidence exists to support this direction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information (Taiwan)
Insulin human is currently not approved or marketed in Taiwan. No regulatory authorization records are on file.
| Item | Content |
|---|---|
| Regulatory Agency | TFDA (Taiwan Food and Drug Administration) |
| Market Status | Not Marketed |
| Total Authorizations | 0 |
Note: Taiwan regulatory prescribing information (TFDA 仿單), including warnings, contraindications, and full safety labeling, has not been retrieved (Data Gap DG001). This information should be obtained directly from the TFDA website before any further evaluation.
Safety Considerations
Please refer to the SmPC or TFDA prescribing information for complete safety data. Full Taiwan regulatory safety labeling (warnings, contraindications) is currently unavailable and must be obtained before any clinical assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial, published literature, or mechanistic evidence supporting insulin human as a direct treatment for autoimmune oophoritis. The TxGNN prediction reflects shared autoimmune endocrine network topology — specifically the co-occurrence of T1DM and APS — rather than any direct therapeutic activity of insulin on ovarian autoimmune processes.
To proceed, the following would be needed:
- Preclinical evidence (animal model or in vitro) demonstrating insulin’s modulation of ovarian autoimmune inflammation
- A plausible mechanistic hypothesis beyond comorbidity co-occurrence (e.g., insulin as an immunomodulator in autoimmune endocrine tissue)
- Taiwan regulatory (TFDA) prescribing information and full safety labeling (DG001 remediation)
- Formal mechanism of action documentation from DrugBank (DG002 remediation)
- Expert consultation with reproductive endocrinology and autoimmunology to assess biological plausibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.